MHC-Peptide Binding: Dimers of Cysteine-Containing Nonapeptides Bind with High Affinity to HLA-A2.1 Class I Molecules

Journal of Immunotherapy

Volumn 20, Issue 6, 1997, Pages 431-436

  Di Modugno, Francesca ^a   Mammi, Caterina ^a   Rosanò, Laura ^a   Rubiu, Oriana ^a   Nisticò, Paola ^a   Chersi, Alberto ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cysteine; Cystine; ErbB 2; HLA A2.1; Peptides

Indexed keywords

CD8 ANTIGEN; CYSTEINE; CYSTINE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PEPTIDE ANALYSIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; CYSTEINE; DIMERIZATION; GLUTATHIONE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2;

EID: 0030775352     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199711000-00002     Document Type: Article

References (24)

1. Falk K, Roetzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-6.
2. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-6.
3. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
4. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gplOO by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995; 55: 4972-9.
5. Visseren MJW, van Elsas A, van der Voort EIH, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995; 154: 3991-8.
6. Toso JF, Oei C, Oshidari F, et al. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res 1996;56:16-20.
7. Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995;41:178-228.
8. Tanigaki N, Fruci D, Chersi A, Butler R. Unfolded HLA class I alpha chains and their use in an assay of HLA class-I-peptide binding. Hum Immunol 1993;36:119-27.
9. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human T cells specific for peptides derived from Her-2/neu protooncogene protein. Cancer Res 1994;54:1071-6.
10. Fisk B, Blevins TL, Wharton JT, Joannides CG. Identification of an immunodominant peptide of Her-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
11. Chen Y, Sidney J, Southwood S, et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J Immunol 1994;152:2874-81.
12. Peoples GE, Goedegebuure PS, Smith R, Linean DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same Herllneu-AtmtA peptide. Proc Natl AcadSci USA 1995;92:432-6.
13. Hynes NE, Stern DF. The biology of erbB-21neulHER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
14. Merrifield RB. Solid-phase peptide synthesis: the synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149-53.
15. Yajima H, Ogawa H, Watanabe H, Fujii N, Kurobe M, Miyamoto S. Studies on peptides: application of the trifluoromethanesulfonic acid procedure to the synthesis of Tufsin. Chem Pharm Bull 1975; 23:371-3.
16. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1969;82:7077-82.
17. Baas BEJ, van Santen H-M, Kleijmeer MJ, Geuze HJ, Peters PJ, Ploegh HL. Peptide-induced stabilization and intracellular localization of empty HLA class I complexes. J Exp Med 1992; 176: 147-56.
18. Brodsky FM, Parham P, Colin J, Barnstable CJ, Crumpton MJ, Bodmer WF. Monoclonal antibodies for analysis of the HLA system. Immunol Rev 1979;47:3-61.
19. Walker BD, Flexner C, Birch-Limberger K, et al. Long term culture and fine specificity of human cytotoxic T-lymphocytes clones reactive with HIV type. Proc Natl Acad Sci USA 1989;86:9514-8.
20. Wang R-F, Appella E, Kawakami Y, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-16.
21. Coussens L, Yang-Feng TL, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
22. Van den Burg SH, Ras E, Drijfhout JW, et al. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Hum Immunol 1995;44:189-98.
23. Heemels M-T, Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 1995; 64:463-91.
24. + breast cancer patients. J Natl Cancer Inst 1997;89/4:319-21.